The G534E-polymorphism of the gene encoding the factor VII-activating protease is a risk factor for venous thrombosis and recurrent events

Copyright © 2012 Elsevier Ltd. All rights reserved.

Bibliographic Details
Published in:Thrombosis research, Vol. 130, No. 3 (2012), p. 441-4
Main Author: Ahmad-Nejad, Parviz (Author)
Other Involved Persons: Dempfle, Carl-Erik ; Weiss, Christel ; Bugert, Peter ; Borggrefe, Martin ; Neumaier, Michael
Format: electronic Article
Item Description:Date Completed 31.01.2013
Date Revised 21.08.2012
published: Print-Electronic
Citation Status MEDLINE
Copyright: From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Physical Description:Online-Ressource
QR Code: Show QR Code
  • Copyright © 2012 Elsevier Ltd. All rights reserved.
  • INTRODUCTION: A single nucleotide polymorphism of the factor VII activating protease (FSAP), FSAP Marburg I (rs7080536) has been identified as a risk factor for venous thrombosis, but its clinical role has so far been controversial in part due to small cohort sizes. The aim of the present case-control study was to elucidate the impact of the FSAP Marburg I polymorphism (FSAP-MI) on the development of venous thromboembolic disease (VTE) with other known sequence variations, including Factor V Leiden (rs6025) and Factor II G20210A (rs1799963)
  • MATERIALS AND METHODS: The study included 891 patients (312 male and 579 female) with a history of deep venous thrombosis (DVT) and/or pulmonary embolism (PE) and 1283 healthy blood donors with no history of venous thromboembolic disease
  • RESULTS: We found that besides to the well-established aforementioned sequence variations of FV and Prothrombin, the FSAP Marburg I (FSAP-MI) polymorphism was significantly associated with the development of DVTs (1.65 (1.16-2.34) OR (95% CI)) and recurrent thromboembolic events (DVT and PE) (2.13 (1.35-3.36) OR (95% CI)). Comparing patients displaying one or more events FSAP-MI was still associated with the development of recurrent thromboembolic events (1.64 (1- 2.69) OR (95% CI))
  • CONCLUSIONS: We conclude that FSAP Marburg-I genotyping may be used to determine the risk for thromboembolic disorders in patients with suspected thrombophilia and known DVT or PE